CytomX Therapeutics (NASDAQ:CTMX) Rating Increased to Buy at BidaskClub
Several other equities analysts also recently issued reports on CTMX. Nomura reduced their price objective on CytomX Therapeutics to $22.00 in a research report on Monday, May 13th. ValuEngine downgraded Zosano Pharma from a buy rating to a hold rating in a research report on Wednesday, May 1st. Mizuho initiated coverage on CytomX Therapeutics in a report on Wednesday, June 12th. They set a buy rating and a $16.00 target price on the stock. Cantor Fitzgerald reissued an overweight rating and set a $23.00 target price (up previously from $21.00) on shares of CytomX Therapeutics in a report on Monday, June 3rd. Finally, Zacks Investment Research cut German American Bancorp. from a buy rating to a hold rating in a report on Tuesday, April 30th. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and ten have given a buy rating to the company’s stock. CytomX Therapeutics presently has an average rating of Buy and an average price target of $20.72.
Shares of NASDAQ CTMX opened at $11.79 on Friday. The company has a debt-to-equity ratio of 0.22, a quick ratio of 4.21 and a current ratio of 4.21. The business’s 50 day simple moving average is $10.80. The firm has a market capitalization of $535.58 million, a P/E ratio of -5.81 and a beta of 0.64. CytomX Therapeutics has a 12-month low of $8.94 and a 12-month high of $27.20.
A number of large investors have recently made changes to their positions in the stock. BNP Paribas Arbitrage SA increased its holdings in shares of CytomX Therapeutics by 84,072.7% in the first quarter. BNP Paribas Arbitrage SA now owns 9,259 shares of the biotechnology company’s stock valued at $100,000 after buying an additional 9,248 shares in the last quarter. Legal & General Group Plc increased its holdings in shares of CytomX Therapeutics by 18.6% in the fourth quarter. Legal & General Group Plc now owns 8,342 shares of the biotechnology company’s stock valued at $126,000 after buying an additional 1,306 shares in the last quarter. Deltec Asset Management LLC bought a new position in shares of CytomX Therapeutics in the first quarter valued at $129,000. Metropolitan Life Insurance Co. NY increased its holdings in shares of CytomX Therapeutics by 376.5% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 13,479 shares of the biotechnology company’s stock valued at $204,000 after buying an additional 10,650 shares in the last quarter. Finally, First Trust Advisors LP bought a new position in shares of CytomX Therapeutics in the first quarter valued at $263,000. 81.81% of the stock is currently owned by hedge funds and other institutional investors.
About CytomX Therapeutics
CytomX Therapeutics, Inc operates as an oncology-focused biopharmaceutical company in the United States. The company develops a novel class of investigational antibody therapeutics based on its Probody technology platform for the treatment of cancer. Its product candidates in clinical stage include CX-072, a Probody therapeutic targeting programmed cell death ligand 1 immuno-oncology target; CX-2009, a Probody drug conjugate (PDC) against CD166 novel drug target; BMS-986249, a CTLA-4 Probody therapeutic drug; CX-2029, a PDC targeting CD71; and CX-188, a Probody therapeutic targeting PD-1 anti-cancer target.
Further Reading: What are the qualifications of a portfolio manager?
Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.